ArticleJournal for immunotherapy of cancer2021

SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.

Esther Redin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.